Kodiak Sciences Inc. (KOD) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGM. Market cap 5.92B USD. 52-week range 10.94 to 104.00 USD. Data as of 2026-10-09.
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular ...